Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) P/S ratio

Alert me on P/S ratio

As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/S ratio of 10.1×. Over the past ten years it has ranged from 6.4× (October 2021) to 54.4× (March 2015); the current reading is higher than 35% of that period. That is in line with the Biotechnology industry median of 9.7× and above the Healthcare sector median of 3.4×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 9.7× 2.49%
FY2024 9.4× (12.16%)
FY2023 10.7× 30.82%
FY2022 8.2× 9.78%
FY2021 7.5× (24.49%)
FY2020 9.9× (26.72%)
FY2019 13.5× (2.35%)
FY2018 13.8× (9.57%)
FY2017 15.3× 42.04%
FY2016 10.8× (63.40%)

Quarterly newest first

Period P/S ratio Change
Jun 2026 10.0× 7.81%
Mar 2026 9.3× (3.86%)
Dec 2025 9.7× 13.12%
Sep 2025 8.5× (14.68%)
42 more quarters

Against its own ten years

Low 6.4× High 54.4×
Ten-year median 11.8×
Current reading's percentile 39

P/S ratio against peers

Company P/S ratio
REGN Regeneron Pharmaceuticals, Inc. compare 5.2×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.4×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.7×
ARGX argenex SE compare 9.6×
VRTX Vertex Pharmaceuticals Incorporated 10.1×
RPRX Royalty Pharma PLC compare 10.8×
MRNA Moderna, Inc. compare 38.9×
RVMD Revolution Medicines, Inc. compare 1,395×
ROIV Roivant Sciences Ltd. compare 3,209×
Biotechnology industry median 9.7×
Healthcare sector median 3.4×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on VRTX